Molecular Profile Detail

Profile Name AKT1 act mut
Gene Variant Detail

AKT1 act mut (gain of function)

Relevant Treatment Approaches Akt Inhibitor (Pan) Akt1 Inhibitor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
AKT1 act mut Advanced Solid Tumor no benefit Akt Inhibitor (Pan) Triciribine Phase I Actionable In a Phase I trial, Triciribine (API-2) demonstrated safety, but lacked efficacy as a monotherapy in advanced solid tumor patients with activated Akt (PMID: 20644979). 20644979
AKT1 act mut lymphoma no benefit Sirolimus Preclinical - Cell line xenograft Actionable In a preclinical study, Rapamune (sirolimus) treatment did not improve survival in cell line xenograft animal models of lymphoma overexpressing constitutively active Akt (PMID: 18708578). 18708578
AKT1 act mut lymphoma decreased response Doxorubicin Preclinical - Cell line xenograft Actionable In a preclinical study, lymphoma cells overexpressing constitutively active Akt demonstrated reduced sensitivity to Adriamycin (doxorubicin) treatment in cell line xenograft models (PMID: 18708578). 18708578
AKT1 act mut lymphoma predicted - sensitive Doxorubicin + Sirolimus Preclinical - Cell line xenograft Actionable In a preclinical study, Rapamune (sirolimus) and Adriamycin (doxorubicin) combination treatment resulted in improved survival and prolonged remission in cell line xenograft animal models of lymphoma overexpressing constitutively active Akt (PMID: 18708578). 18708578
Clinical Trial Phase Therapies Title Recruitment Status
NCT02549989 Phase II LY3023414 Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer Active, not recruiting
NCT01833169 Phase II Buparlisib BKM120 for Patients With PI3K-activated Tumors Completed